Decreased γ-aminobutyric acid levels in the parietal region of patients with Alzheimer's disease

Xue Bai, Richard A E Edden, Fei Gao, Guangbin Wang, Lebin Wu, Bin Zhao, Minzhong Wang, Queenie Chan, Weibo Chen, Peter B Barker, Xue Bai, Richard A E Edden, Fei Gao, Guangbin Wang, Lebin Wu, Bin Zhao, Minzhong Wang, Queenie Chan, Weibo Chen, Peter B Barker

Abstract

Purpose: To determine whether there are in vivo differences of γ-aminobutyric acid (GABA) levels in frontal and parietal regions of Alzheimer's disease (AD) patients, compared with healthy controls using magnetic resonance spectroscopy ((1) H-MRS).

Materials and methods: Fifteen AD patients and fifteen age- and gender-matched healthy controls underwent (1) H-MRS of the frontal and parietal lobes using the "MEGA-Point Resolved Spectroscopy Sequence" (MEGA-PRESS) technique, and cognitive levels of subjects were evaluated using Mini-Mental State Examination (MMSE) tests. MRS data were processed using the Gannet program. Because the signal detected by MEGA-PRESS includes contributions from GABA, macromolecules and homocarnosine, it is labeled as "GABA+" rather than GABA. Differences of GABA+/Cr ratios between AD patients and controls were tested using covariance analysis, adjusting for gray matter fraction. The relationship between GABA+/Cr and MMSE scores was also analyzed.

Results: Significant lower GABA+/Cr ratios were found in the parietal region of AD patients compared with controls (P = 0.041). In AD patients, no significant correlations between GABA+/Cr and MMSE scores were found in either the frontal (r = -0.164; P = 0.558) or parietal regions (r = 0.025; P = 0.929).

Conclusion: Decreased GABA+/Cr levels were present in the parietal region of patients with AD in vivo, suggesting that abnormalities of the GABAergic system may be present in the pathogenesis of AD.

Keywords: 1H-MRS; Alzheimer's disease; GABA; MEGA-PRESS; MMSE.

© 2014 Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
The position of voxels, corresponding segmentation data and representative spectra. The (a,d) and (b,e) panels show the position of volumes of interest in frontal (upper) and parietal regions (lower) on sagittal and coronal T1-weighted TFE images in an AD patient. The corresponding results of brain segmentation are shown in the frontal (c) and parietal regions (f). (g, h) Show the representative MEGA-PRESS spectra processed using the “Gannet 2.0” toolkit in frontal and parietal regions of AD. (g) Shows the curve-fitting of the GABA peak using Gannet, the red lines in the panels are the results of the GannetFit curve-fitting, the blue lines show the postphase and frequency aligned GABA data, and the black line is the residual difference between the experimental data and the curve-fit. (h) is the MEGA-PRESS difference spectrum. The Glx, GABA and MM peaks resonate at 3.7, 3.0 ppm and 0.9 ppm respectively.
Figure 2
Figure 2
The GABA+/Cr ratios of AD patients and HC in frontal (a) and parietal (b) regions. The mean and standard deviation of GABA+/Cr ratios are displayed. a: Shows that the mean GABA+/Cr ratios are lower in AD than in HC in frontal region (P = 0.345), but no statistical difference is detected. There does appear to be one “outlier” value in the control group, however, no significant differences are found in this region between AD and HC, whether this point is included or not. b: Shows GABA+/Cr ratios of AD group are significantly decreased in the parietal region (P = 0.041).

References

    1. Lanctot KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer’s disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry. 2004;49:439–453.
    1. Obata K. Synaptic inhibition and gamma-aminobutyric acid in the mammalian central nervous system. Proc Jpn Acad Ser B Phys Biol Sci. 2013;89:139–156.
    1. Seidl R, Cairns N, Singewald N, Kaehler ST, Lubec G. Differences between GABA levels in Alzheimer’s disease and Down syndrome with Alzheimer-like neuropathology. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:139–145.
    1. Ball S, Busatto GF, David AS, et al. Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I-iomazenil SPET study. Biol Psychiatry. 1998;43:107–117.
    1. Marczynski TJ. GABAergic deafferentation hypothesis of brain aging and Alzheimer’s disease revisited. Brain Res Bull. 1998;45:341–379.
    1. Bartha R, Smith M, Rupsingh R, Rylett J, Wells JL, Borrie MJ. High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:786–793.
    1. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998;11:266–272.
    1. Choi IY, Lee SP, Merkle H, Shen J. In vivo detection of gray and white matter differences in GABA concentration in the human brain. Neuroimage. 2006;33:85–93.
    1. Yoon JH, Maddock RJ, Rokem A, et al. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J Neurosci. 2010;30:3777–3781.
    1. Huang W, Alexander GE, Chang L, et al. Brain metabolite concentration and dementia severity in Alzheimer’s disease: a (1)H MRS study. Neurology. 2001;57:626–632.
    1. Gmitrowicz A, Kucharska A. Developmental disorders in the fourth edition of the American classification: diagnostic and statistical manual of mental disorders (DSM IV – optional book) Psychiatr Pol. 1994;28:509–521.
    1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–944.
    1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.
    1. Rothman DL, Behar KL, Prichard JW, Petroff OA. Homocarnosine and the measurement of neuronal pH in patients with epilepsy. Magn Reson Med. 1997;38:924–929.
    1. Edden RAE, Puts NA, Harris AD, Barker PB, Evans CJ. Gannet: a batch-processing tool for the quantitative analysis of GABA-edited MRS spectra. J Magn Reson Imaging. 2013 doi: 10.1002/jmri.24478. (in press)
    1. Near J, Edden R, Evans CJ, Paquin R, Harris A, Jezzard P. Frequency and phase drift correction of magnetic resonance spectroscopy data by spectral registration in the time domain. Magn Reson Med. 2014 doi: 10.1002/mrm.25094. (in press)
    1. Graff-Radford J, Kantarci K. Magnetic resonance spectroscopy in Alzheimer’s disease. Neuropsychiatr Dis Treat. 2013;9:687–696.
    1. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology. 2001;56:592–598.
    1. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 2001;20:45–57.
    1. Roebuck JR, Windham JP, Hearshen DO. Segmentation of MRS signals using ASPECT (analysis of SPectra using Eigenvector Decomposition of Targets) Med Phys. 1994;21:277–285.
    1. Kelsom C, Lu W. Development and specification of GABAergic cortical interneurons. Cell Biosci. 2013;3:19.
    1. Lowe SL, Francis PT, Procter AW, Palmer AM, Davison AN, Bowen DM. Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer’s disease. Brain. 1988;111:785–799.
    1. Sasaki H, Muramoto O, Kanazawa I, Arai H, Kosaka K, Iizuka R. Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Ann Neurol. 1986;19:263–269.
    1. Ellison DW, Beal MF, Mazurek MF, Bird ED, Martin JB. A postmortem study of amino acid neurotransmitters in Alzheimer’s disease. Ann Neurol. 1986;20:616–621.
    1. Nilsen LH, Melo TM, Saether O, Witter MP, Sonnewald U. Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer’s disease: a longitudinal in vivo 1 H MRS study. J Neurochem. 2012;123:532–541.
    1. Mlynarik V, Cacquevel M, Sun-Reimer L, et al. Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer’s disease. J Alzheimers Dis. 2012;31:S87–S99.
    1. Kugler P. Enzymes involved in glutamatergic and GABAergic neurotransmission. Int Rev Cytol. 1993;147:285–336.
    1. Krantic S, Isorce N, Mechawar N, et al. Hippocampal GABAergic neurons are susceptible to amyloid-beta toxicity in vitro and are decreased in number in the Alzheimer’s disease TgCRND8 mouse model. J Alzheimers Dis. 2012;29:293–308.
    1. Hanyu H, Kume K, Sato T, et al. Regional differences in cortical benzodiazepine receptors of Alzheimer, vascular, and mixed dementia patients. J Neurol Sci. 2012;323:71–76.
    1. Pappata S, Varrone A, Vicidomini C, et al. SPECT imaging of GABA(A)/benzodiazepine receptors and cerebral perfusion in mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2010;37:1156–1163.
    1. Rissman RA, De Blas AL, Armstrong DM. GABA(A) receptors in aging and Alzheimer’s disease. J Neurochem. 2007;103:1285–1292.
    1. Luchetti S, Bossers K, Van de Bilt S, et al. Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer’s disease. Neurobiol Aging. 2011;32:1964–1976.
    1. Edden RA, Puts NA, Barker PB. Macromolecule-suppressed GABA-edited magnetic resonance spectroscopy at 3T. Magn Reson Med. 2012;68:657–661.
    1. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000;13:129–153.
    1. Clerx L, van Rossum IA, Burns L, et al. Measurements of medial temporal lobe atrophy for prediction of Alzheimer’s disease in subjects with mild cognitive impairment. Neurobiol Aging. 2013;34:2003–2013.
    1. Oosterman JM, Oosterveld S, Rikkert MG, Claassen JA, Kessels RP. Medial temporal lobe atrophy relates to executive dysfunction in Alzheimer’s disease. Int Psychogeriatr. 2012;24:1474–1482.
    1. Visser PJ, Verhey FR, Hofman PA, Scheltens P, Jolles J. Medial temporal lobe atrophy predicts Alzheimer’s disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry. 2002;72:491–497.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir